Using NGS-Based Proteomics to Differentiate BTK Inhibitor Response in Leukemia
Date: Feb 18, 2025
This webinar will highlight a study that compares the effect of three different BTK inhibitors: ibrutinib, acalabrutinib, and zanubrutinib. Patient samples were obtained before and at various time points after treatment to identify biomarkers that could be informative of the treatment’s effects.
Application focusAdvancing Precision Medicine in Inflammatory Diseases with Affinity-Based Proteomics
Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting joints, entheses, and skin, and is linked to higher risks of cardiovascular disease and MASLD. These associations reflect complex inflammation-metabolism interactions, but treatment effects remain unclear.
10 Apr 2025
- Application focus
Integrating plasma proteomics to identify tuberculosis-specific diagnostic biomarkers
Using mass spectrometry, Olink’s proximity extension assay, cross-disciplinary research, and international collaboration, Dr. Schiff and team have identified protein biomarkers with high TB-specificity and demonstrated the diagnostic performance of a six-protein diagnostic panel.
05 Dec 2024
- Application focus
Immune-competent vascularized human cerebral organoids to study brain development and disease: a multiomics approach
The Network Biology Collaborative Centre at Mount Sinai Hospital, an Olink Certified Service Provider, present their application of Olink’s Proximity Extension Assay technology to profile an organoid-based model that provides novel regulatory and mechanistic insights into human brain development.
13 Feb 2025